Selected Base Case Input Parameters in an Analysis of Long-Acting Cabotegravir-Rilpivirine With Wraparound Services Compared With Oral Integrase Inhibitor–Based Antiretroviral Therapy With or Without Wraparound Services for Nonsuppressed People With HIV Experiencing Adherence Barriers
| Parameter . | Value . | Source . | |
|---|---|---|---|
| Cohort characteristics | Derived from [15] | ||
| Age, y, mean (SD) | 47 (10) | ||
| Sex at birth, male/female % | 90/10 | ||
| CD4 count, cells/µL, mean (SD) | 150 (75) | ||
| Adherence distribution on oral INSTI-based ART | Without WS | With WS | Derived from [7] |
| Mean, % | 65 | 67 | |
| Proportion with MPR 50%–66% | 63 | 32 | |
| Proportion with MPR 66%–70% | 35 | 57 | |
| Proportion with MPR 70%–95% | 2 | 10 | |
| HIV RNA suppression at 3 mo after ART initiation | |||
| INSTI, INSTI/WS | 13% | 28% | [7, 21–25] |
| CAB-RPV/WS | NA | 60% | [15] |
| Subsequent rates of viremia, per 100 PY | |||
| INSTI, INSTI/WS | 7.37 | 7.19 | [7, 21–25] |
| CAB-RPV/WS | NA | 3.29 | [26] |
| Engagement in care | |||
| Loss to follow-up rate, per 100 PY, mean (SD) | 28 (2) | 16 (1) | Derived from [7, 27] |
| Return to care rate, per 100 PY | 18 | 18 | [28] |
| RMR of non-HIV-related mortality vs the general population | 9 | 9 | [29] |
| Parameter . | Value . | Source . | |
|---|---|---|---|
| Cohort characteristics | Derived from [15] | ||
| Age, y, mean (SD) | 47 (10) | ||
| Sex at birth, male/female % | 90/10 | ||
| CD4 count, cells/µL, mean (SD) | 150 (75) | ||
| Adherence distribution on oral INSTI-based ART | Without WS | With WS | Derived from [7] |
| Mean, % | 65 | 67 | |
| Proportion with MPR 50%–66% | 63 | 32 | |
| Proportion with MPR 66%–70% | 35 | 57 | |
| Proportion with MPR 70%–95% | 2 | 10 | |
| HIV RNA suppression at 3 mo after ART initiation | |||
| INSTI, INSTI/WS | 13% | 28% | [7, 21–25] |
| CAB-RPV/WS | NA | 60% | [15] |
| Subsequent rates of viremia, per 100 PY | |||
| INSTI, INSTI/WS | 7.37 | 7.19 | [7, 21–25] |
| CAB-RPV/WS | NA | 3.29 | [26] |
| Engagement in care | |||
| Loss to follow-up rate, per 100 PY, mean (SD) | 28 (2) | 16 (1) | Derived from [7, 27] |
| Return to care rate, per 100 PY | 18 | 18 | [28] |
| RMR of non-HIV-related mortality vs the general population | 9 | 9 | [29] |
Abbreviations: ART, antiretroviral therapy; CAB-RPV/WS, long-acting injectable cabotegravir-rilpivirine with wraparound services; HIV, human immunodeficiency virus; INSTI, oral integrase inhibitor–based antiretroviral therapy; INSTI/WS, oral integrase inhibitor–based antiretroviral therapy with wraparound services; MPR, medication possession ratio; NA, not applicable; PY, person-years; RMR, relative mortality ratio; SD, standard deviation; WS, wraparound services.
Selected Base Case Input Parameters in an Analysis of Long-Acting Cabotegravir-Rilpivirine With Wraparound Services Compared With Oral Integrase Inhibitor–Based Antiretroviral Therapy With or Without Wraparound Services for Nonsuppressed People With HIV Experiencing Adherence Barriers
| Parameter . | Value . | Source . | |
|---|---|---|---|
| Cohort characteristics | Derived from [15] | ||
| Age, y, mean (SD) | 47 (10) | ||
| Sex at birth, male/female % | 90/10 | ||
| CD4 count, cells/µL, mean (SD) | 150 (75) | ||
| Adherence distribution on oral INSTI-based ART | Without WS | With WS | Derived from [7] |
| Mean, % | 65 | 67 | |
| Proportion with MPR 50%–66% | 63 | 32 | |
| Proportion with MPR 66%–70% | 35 | 57 | |
| Proportion with MPR 70%–95% | 2 | 10 | |
| HIV RNA suppression at 3 mo after ART initiation | |||
| INSTI, INSTI/WS | 13% | 28% | [7, 21–25] |
| CAB-RPV/WS | NA | 60% | [15] |
| Subsequent rates of viremia, per 100 PY | |||
| INSTI, INSTI/WS | 7.37 | 7.19 | [7, 21–25] |
| CAB-RPV/WS | NA | 3.29 | [26] |
| Engagement in care | |||
| Loss to follow-up rate, per 100 PY, mean (SD) | 28 (2) | 16 (1) | Derived from [7, 27] |
| Return to care rate, per 100 PY | 18 | 18 | [28] |
| RMR of non-HIV-related mortality vs the general population | 9 | 9 | [29] |
| Parameter . | Value . | Source . | |
|---|---|---|---|
| Cohort characteristics | Derived from [15] | ||
| Age, y, mean (SD) | 47 (10) | ||
| Sex at birth, male/female % | 90/10 | ||
| CD4 count, cells/µL, mean (SD) | 150 (75) | ||
| Adherence distribution on oral INSTI-based ART | Without WS | With WS | Derived from [7] |
| Mean, % | 65 | 67 | |
| Proportion with MPR 50%–66% | 63 | 32 | |
| Proportion with MPR 66%–70% | 35 | 57 | |
| Proportion with MPR 70%–95% | 2 | 10 | |
| HIV RNA suppression at 3 mo after ART initiation | |||
| INSTI, INSTI/WS | 13% | 28% | [7, 21–25] |
| CAB-RPV/WS | NA | 60% | [15] |
| Subsequent rates of viremia, per 100 PY | |||
| INSTI, INSTI/WS | 7.37 | 7.19 | [7, 21–25] |
| CAB-RPV/WS | NA | 3.29 | [26] |
| Engagement in care | |||
| Loss to follow-up rate, per 100 PY, mean (SD) | 28 (2) | 16 (1) | Derived from [7, 27] |
| Return to care rate, per 100 PY | 18 | 18 | [28] |
| RMR of non-HIV-related mortality vs the general population | 9 | 9 | [29] |
Abbreviations: ART, antiretroviral therapy; CAB-RPV/WS, long-acting injectable cabotegravir-rilpivirine with wraparound services; HIV, human immunodeficiency virus; INSTI, oral integrase inhibitor–based antiretroviral therapy; INSTI/WS, oral integrase inhibitor–based antiretroviral therapy with wraparound services; MPR, medication possession ratio; NA, not applicable; PY, person-years; RMR, relative mortality ratio; SD, standard deviation; WS, wraparound services.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
